BROWSE BY STUDY TYPE OR CONFERENCE
All
- All
- MODEL VALIDATION
- CLINICAL VALIDATION
- AACR
- ASCO
- ASH
BROWSE BY YEAR
All
- All
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- Archive
Therapy Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Is Predictive of Individual Acute Myeloid Leukemia (AML) Patient Probability of Clinical Response (CR) and Overall Survival (OS): Mycare-023
ASH Annual Meeting, 2021
Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Identifies Immune Modulation As a Key Pathway for Predicting Azacitidine (AZA) Response in Myelodysplastic Syndromes (MDS)
ASH Annual Meeting, 2021
Cellworks CBM identifies Novel Biomarkers to Inform Mitoxantrone, Etoposide, and Cytarabine (MEC)-Based Combination Therapy in Refractory & Relapsed Acute Myeloid Leukemia (AML) Patients
ASH Annual Meeting, 2021
Impact of KRAS and Co-occurring Mutations on NSCLC Master Regulator Network as Determined by Computational Omics Biology Model.
Journal of Thoracic Oncology, 2021
Computational Omics Biology Model (CBM) Identifies PD-L1 Immunotherapy Response Criteria Based on Genomic Signature of NSCLC
Journal of Thoracic Oncology, 2021
Computational Omics Biology Model (CBM) Identifies Amplifications of Chromosome 6p to Predict Chemotherapy Resistance
Journal of Thoracic Oncology, 2021
Computational Omics Biology Model (CBM) Identifies Novel Biomarkers to Inform Combination Platinum Compound Therapy in NSCLC
Journal of Thoracic Oncology, 2021
Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type
Oncotarget, 2021
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
Journal of Neuro-Oncology , 2021
Superior overall survival (OS) and disease-free survival (DFS) predictions for patients with glioblastoma multiforme (GBM) using Cellworks Singula: myCare-022-03.
ASCO Meeting Library, 2021
Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.
ASCO Meeting Library, 2021
Cellworks Omics Biology Model (CBM) to predict therapy response and identify biomarkers for all-trans retinoic acid (ATRA) benefit as addition to induction chemotherapy in adults with acute myeloid leukemia (AML).
ASCO Meeting Library, 2021
Cellworks Omics Biology Model (CBM) to identify amplifications of chromosome 11p and 1p predict paclitaxel and carboplatin resistance.
ASCO Meeting Library, 2021
Cellworks Omics Biology Model (CBM) to predict therapy response and identify novel biomarkers for 5FU-based combination therapy in gastric cancer patients.
ASCO Meeting Library, 2021
Cellworks Omics Biology Modeling (CBM) to predict therapy response and identifies novel biomarkers for carboplatin/cisplatin along with pemetrexed in NSCLC patients.
ASCO Meeting Library, 2021
Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: myCare-020-01
Blood Journal, 2020
Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singula™: myCare-020-02
Blood Journal, 2020
Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach
Blood Journal, 2020
Prediction of Clinical Response for Frontline Treatment of Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-02
Blood Journal, 2020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
The Lancet Oncology, 2020
Superior therapy response predictions for patients with acute myeloid leukemia (AML) using Cellworks Singula: MyCare-009-01
ASCO Meeting Library, 2020
Superior therapy response predictions for patients with myelodysplastic syndrome (MDS) using Cellworks Singula: MyCare-009-02
ASCO Meeting Library, 2020
Superior therapy response predictions for patients with glioblastoma (GBM) using Cellworks Singula: MyCare-009-03
ASCO Meeting Library, 2020
Superior therapy response predictions for patients with low-grade glioma (LGG) using Cellworks Singula: MyCare-009-04
ASCO Meeting Library, 2020
Superior therapy response predictions for patients with pancreatic cancer (PDAC) using Cellworks Singula: MyCare-009-05
ASCO Meeting Library, 2020
Combination chemotherapy versus temozolomide (TMZ) for patients with MGMT methylated (m-MGMT) glioblastoma (GBM): Results of cellworks omics biosimulation—myCare-015
ASCO Meeting Library, 2020
Prediction of Outcomes With a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated With Radiation Therapy and Temozolomide
International Journal of Radiation Oncology, Biology, Physics, 2020
A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents
ASH Annual Meeting, 2019
Role of mTOR Inhibitor Everolimus in the Treatment of Metastatic Thymic Epithelial Tumors
Journal of Thoracic Oncology, 2019
A feedforward relationship between active Rac1 and phosphorylated Bcl-2 is critical for sustaining Bcl-2 phosphorylation and promoting cancer progression
Science Direct, 2019
Computational Models Accurately Predict Multi-Cell Biomarker Profiles in Inflammation and Cancer
Nature, Scientific Reports, 2019
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients
Blood Advances, 2019
Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics.
Leukemia Research, 2019
Predicting response to BET inhibitors using computational modeling: A BEAT AML project study
Leukemia Research, 2019
Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study
Blood Journal, 2018
AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow
Blood Journal, 2018
Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics
Blood Journal, 2018
Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome
Blood Journal, 2018
Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study
Blood Journal, 2018
Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort
Blood Journal, 2018
Clinical Validation of Treatment Response Predictions Using a Genomics Driven Computational Biology Modelling Multiple Myeloma Algorithm
Blood Journal, 2018
Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System
Blood Journal, 2018
Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model
Journal of Thoracic Oncology, 2018
Computational Biological Model Prediction of PD-L1 Expression and Immunotherapy Response for KRAS Mutated Lung Cancer Based on Co-Mutations
Journal of Thoracic Oncology, 2018
iCare 1: A prospective clinical trial to predict treatment response based on genomics-informed computational biology in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
ASCO Annual Meeting, 2018
Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
BMC Cancer, 2018
A Study to Predict Response to Azacitidine or Lenalidomide/Azacitidine Combination Therapy in MDS and AML Patients Using a Computational Biological Modeling (CBM) Approach
Blood Journal, 2017
Computational Biology Approach to Predict Hypomethylating Agent (HMA) Response Using Genomic and Clinical Characteristics in Myelodsyplastic Syndromes (MDS)
Blood Journal, 2017
Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation
Blood Journal, 2017
Computational Biology Model of ETP-ALL Used to Accurately Classify ETP-ALL Vs Non ETP-ALL Patients with Genomic Input
Blood Journal, 2017
Computational Modeling of Protein Networks Predicts Treatment Outcomes in Multiple Myeloma (MM)
Blood Journal, 2017
Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options
Blood Journal, 2017
Personalized Therapy Design for Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Using Computational Biology Modeling with in Vitro Validation
Blood Journal, 2017
The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib
Blood Journal, 2017
Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and it's Validation: A Beat AML Project Study
Blood Journal, 2017
Predicting Response to BET Inhibitors Using a Computational Model and it's Validation: A Beat AML Project Study
Blood Journal, 2017
Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and it's Validation: A Beat AML Project Study
Blood Journal, 2017
A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing
Blood Journal, 2017
Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.
Oral Surgery Oral Medicine Oral Pathology Oral Radiology, 2017
A computational biology method to predict HMA or lenalidomide treatment response in non-Del(5q) MDS
AACR Annual Meeting, 2017
iCare 1: A prospective clinical trial to predict treatment response based on mutanome-informed computational biology in patients with AML and MDS
AACR Annual Meeting, 2017
Personalized Therapeutics and Target Identification for Oral Diseases
AADR Annual Meeting, 2017
HBD3 Induced PD-L1 Expression in HNSCC
AADR Annual Meeting, 2017
Determination of Immune Evasion Phenotypes of HNSCC
AADR Annual Meeting, 2016
Detection of PD-L1 expression on HNSCC cells
AADR Annual Meeting, 2016
PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression
Translational Cancer Research, 2016
Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response
Blood Journal, 2016
A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patient with AML and MDS
Blood Journal, 2016
A Genomic Rule Predicting HMA Treatment Response in MDS Identified By Protein Network Mapping and Validated By Clinical Trial Simulation
Blood Journal, 2016
Use of Genomic Information to Predict Treatment Response in Multiple Myeloma Patients By Computational Mapping of Protein Network Disturbances
Blood Journal, 2016
Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.
Leukemia Research, 2016
Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models
Cancer Immunology, Immunotherapy, 2016
Predicting Clinical outcomes in cancer patients based on novel computational biology method of mapping the cancer mutanome
AACR Annual Meeting, 2016
Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome
Blood Journal, 2015
Predicting Non-Responders to Immunotherapy Treatments through Simulation of NGS Information
Blood Journal, 2015
Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In silico Target Identification and in vitro Validation
Blood Journal, 2015
Overexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide
Oncotarget, 2015
In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment
Antimicrobial Agents and Chemotherapy, 2015
Predictive simulation-driven personalization methodology for refractory multiple myeloma
AACR Annual Meeting, 2015
Identification and therapeutic targeting of signaling pathways in Ruxolitinib resistant cells
AACR Annual Meeting, 2015
Effectiveness of Predictive Simulation in Identifying Potential Patient-Specific Therapeutic Targets in Multiple Myeloma-A Pilot Study
AACR Annual Meeting, 2015
Personalization of cancer treatment using predictive simulation.
Journal of Translational Medicine, 2015
A Novel and Personalized Method using Simulation for Predicting Effective Therapeutics for Waldenströms Macroglobulinemia
Blood Journal, 2014
Personalized Therapy Design for MPN Using Predictive Simulation Methodology with In Vitro, Ex Vivo, and In Vivo Validation
Blood Journal, 2014
Therapy Personalization Using Predictive Simulation Approach with Ex Vivo Clinical Validations
Blood Journal, 2014
In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
British Journal of Cancer, 2014
Predictive Simulation Approach for Designing Cancer Therapeutic Regimens with Novel Biological Mechanisms
Journal of Cancer, 2014
Predicting GBM response to targeted therapeutics using simulation with ex vivo validations
ASCO Annual Meeting, 2014
Predictive analysis of microenvironment impact on clinical outcomes to drug agents using simulation of myeloproliferative neoplasms
ASCO Annual Meeting, 2014
In silico modeling predicts drug sensitivity of patient-derived cancer cells
Journal of Translational Medicine, 2014
Individualized therapy identified using simulation for bortezomib resistant patient with ex vivo validation
AACR Annual Meeting, 2014
A Predictive Model of an Oral Inflammatory Response
AADR Annual Meeting & Exhibition, 2014
Histatin 5 binds to Porphyromonas gingivalis hemagglutinin B (HagB) and alters HagB-induced chemokine responses
Nature, Scientific Reports, 2014
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance
British Journal of Haematology, 2014
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
Journal of Translational Medicine, 2014
Ex Vivo Patient-Specific Validation of Personalized Therapeutic Designed for Multiple Myeloma
Blood Journal, 2013
Predictive Simulation Based Design and Validation of Repurposed Novel Therapeutics with Multi-Target Mechanisms for Multiple Myeloma
Blood Journal, 2013
Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3
British Journal of Pharmacology, 2013
Oral inflammation, a role for antimicrobial peptide modulation of cytokine and chemokine responses
Expert Review of Anti-infective Therapy, 2013
β-Caryophyllene oxide Inhibits Constitutive and Inducible STAT3 Signaling Pathway Through Induction of the SHP-1 Protein Tyrosine Phosphatase
Molecular Carcinogenesis, 2013
Elastin sequences trigger transient proinflammatory responses by human dermal fibroblasts
The FASEB Journal, 2013
In vitro validation of rationally designed therapeutic based on drug repositioning and combinations
AACR Annual Meeting, 2013
Computer Based “Virtual Tumor” simulation identifies novel use for existing drugs-implication for personalized cancer therapy
AACR Annual Meeting, 2013
STAT3 phosphorylation and Bcl-2 expression as a predictive signature for stratifying clinical lymphomas
AACR Annual Meeting, 2013
Genetic and chemical knockdown: a complementary strategy for evaluating an anti-infective target
Advances and Applications in Bioinformatics and Chemistry, Dovepress, 2013
Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus
Nature, Scientific Reports, 2013
Predictive Software-Based Mathematical Modeling: A Novel Approach to Development of Oral Therapies for Rheumatoid Arthritis – Validation in a Murine Collagen Induced Arthritis Model.
ACR/ARHP Annual Meeting, 2012
Novel Combination Therapy of existing repurposed therapies, designed by predictive software modeling, shows profound impact on disease progression in a murine Collagen-Induced Arthritis (CIA) model
ACR/ARHP Annual Meeting, 2012
Isorhamnetin inhibits proliferation, invasion, and induces apoptosis through modulation of peroxisome proliferator-activated receptor-gamma activation pathway in gastric cancer.
Journal of Biological Chemistry, 2012
STAT3 is a critical mediator of the pro-survival effect of Bcl-2-Rac1 interaction in human cancer cells
AACR Annual Meeting, 2012
Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
Journal of Cell Physiology, 2012
Amplification and demultiplexing in the insulin regulated akt pathway in adipocytes
Journal of Biological Chemistry, 2011
Solid pseudopapillary tumor and wnt signaling pathway...Waytogo!?
Journal of Gastroenterology and Hepatology, 2011
Celastrol Inhibits Proliferation and Induces Chemosensitization through downregulation of NF-κB and STAT3 Regulated Gene Products in Multiple Myeloma Cells
British Journal of Pharmacology, 2011
Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4
Molecular Cancer, 2011
Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A novel approach for overcoming resistance in anticancer treatment
European Journal of Pharmacology, 2011
Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice.
Journal of Molecular Medicine, 2011
Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo.
Clinical Cancer Research, 2011
A kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli
Advances and Applications in Bioinformatics and Chemistry, 2010
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Molecular Cancer Therapeutics, 2010
Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line
Cancer Chemotherapy and Pharmacology, 2010
Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for Parkinson’s disease
Bioorganic & Medicinal Chemistry, 2010
Virtual prototyping study shows increased ATPase activity of Hsp90 to be the key determinant of cancer phenotype
Systems and Synthetic Biology, 2010
A virtual cell system prototyping for development and validation of skin lightening actives: Correlation with ex vivo and in vivo results
Journal of the American Academy of Dermatology, 2009
Insights into the effects of α-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson disease:validation by cell culture data
Free Radical Biology and Medicine, 2008
Insights into the anti-inflammatory actions of Soluble Epoxide Hydrolase Inhibitors through a System’s Biology based in silico modeling approach
The FASEB Journal, 2008
Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for Parkinson's disease explained via in silico studies
Free Radical Biology and Medicine, 2008
Integrating glutathione metabolism and mitochondrial dysfunction with implications for parkinson’s disease:a dynamic model
Neuroscience, 2007
Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis